Identifying mutant pathways in the histiocytoses

Blood

Volumn 124, Issue 19, 2014, Pages 2901-2903

  Prince, H Miles ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MAP2K1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NRAS PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN;

ENZYME PHOSPHORYLATION; ERDHEIM CHESTER DISEASE; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENOTYPE; HUMAN; LANGERHANS CELL HISTIOCYTOSIS; MONOCYTE; MUTATIONAL ANALYSIS; PATHOGENESIS; PYROSEQUENCING; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT RESPONSE; FEMALE; GENETICS; MALE; METABOLISM;

ERDHEIM-CHESTER DISEASE; FEMALE; GTP PHOSPHOHYDROLASES; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; MALE; MAP KINASE KINASE 1; MEMBRANE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84909606802     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-597765     Document Type: Review

References (10)

1. Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007-3015.
2. Emile J-F, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124(19):3016-3019.
3. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
4. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
5. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669-683.
6. Blombery P, Wong SQ, Lade S, Prince HM. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol. 2012;30(32):e331-e332.
7. Hervier B, Haroche J, Arnaud L, et al; on behalf of the French Histiocytoses Study Group. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014;124(7):1119-1126.
8. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-1500.
9. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483-492.
10. Cangi MG, Biavasco R, Cavalli G, et al. BRAFV600Emutation is invariably present and associated to oncogeneinduced senescence in Erdheim-Chester disease [published online ahead of print March 26, 2014]. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204924.